Description
Retatrutide (LY3437943) is a first-in-class triple agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This innovative triple mechanism delivers superior weight loss, increased energy expenditure, and enhanced hepatic fat oxidation compared to dual agonists. In the Phase 2 trial, it achieved a mean weight reduction of 24.2% at 48 weeks; the Phase 3 TRIUMPH-4 trial showed approximately 28–29% average weight loss at 68 weeks, along with significant knee pain improvement. It also offers strong benefits in liver fat reduction, HbA1c lowering, and cardiovascular risk markers, with primarily gastrointestinal side effects typical of incretin therapies. Retatrutide represents the next generation of highly effective metabolic treatments. This content is for research purposes only and is provided solely for reference. It must not be interpreted as health, clinical, or legal advice or guidance.
Effects
Helps reduce appetite and enhance satiety; supports research related to reductions in body weight and body fat; improves markers of blood glucose control and insulin sensitivity; promotes energy expenditure and fat metabolism; may help improve metabolic markers related to blood lipids and fatty liver.
Usage
For research or compliant clinical research use only; typically administered as a subcutaneous injection after reconstitution by qualified professionals according to a research protocol or physician guidance; dosage, titration schedule, and treatment duration must be determined based on a formal research protocol. Low-dose initiation with gradual titration is recommended; do not increase the dose independently or use long term without supervision.
Suitable for
Research subjects with obesity- or overweight-related metabolic conditions; weight management or fat-loss research projects; research subjects related to type 2 diabetes or insulin resistance; individuals who require use under monitoring by professional medical or research institutions.
Not suitable for
Pregnant or breastfeeding women; minors; individuals allergic to Retatrutide or similar peptide ingredients; individuals with a history of pancreatitis or severe gastrointestinal disease; individuals with a family or personal history of medullary thyroid carcinoma or MEN2; patients with severe hepatic or renal impairment or uncontrolled major cardiovascular disease; individuals intending to use it personally without professional guidance.
Ingredients
Retatrutide peptide lyophilized powder; example specification: 5mg/vial, 10 vials/box; excipients are subject to the actual batch COA or label.
Storage
Unreconstituted lyophilized powder should be stored protected from light, sealed, and at low temperature. Long-term storage is typically at -20℃. After reconstitution, store refrigerated at 2-8℃ and use as soon as possible.
